Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors
- 16 November 2010
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 68 (2) , 505-511
Abstract
LY2181308 is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue. This phase I dose escalation study evaluated the tolerability, pharmacokinetics, and anticancer activity of LY2181308 in Japanese.Keywords
This publication has 20 references indexed in Scilit:
- 3,3′-Diindolylmethane Enhances Taxotere-Induced Apoptosis in Hormone-Refractory Prostate Cancer Cells through Survivin Down-regulationCancer Research, 2009
- Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cellsCancer Letters, 2008
- Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cellsJournal of Experimental Medicine, 2007
- Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosisJournal of Hepatology, 2007
- Predicting drug response and toxicity based on gene polymorphismsCritical Reviews in Oncology/Hematology, 2005
- Toxicology of antisense therapeuticsToxicology and Applied Pharmacology, 2004
- Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphomaLeukemia, 2004
- PHARMACOKINETICS OF A TUMOR NECROSIS FACTOR-α PHOSPHOROTHIOATE 2′-O-(2-METHOXYETHYL) MODIFIED ANTISENSE OLIGONUCLEOTIDE: COMPARISON ACROSS SPECIESDrug Metabolism and Disposition, 2003
- Validating survivin as a cancer therapeutic targetNature Reviews Cancer, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000